- My News
- All News
- Most Popular
We break down five of the week's most important and most read stories in healthtech.
Ginger spices up offering with Headspace
Provider of on-demand mental health services Ginger is merging with Headspace, best known for its meditation app, to create a company worth $3 billion.
The newly merged Headspace Health will be able to address mental health needs - from prevention to clinical care - on a single smartphone-based platform.
In Credit Suisse’s July bi-annual investor sentiment survey, Ginger and Headspace were among the most favoured digital health investment picks.
Trouble brews, post-Grail grab
Illumina’s maverick move to close its acquisition of Grail whilst the transaction is being probed for anti-competitiveness has not been well received by regulators.
The EU Commission is now looking to open up a new, separate investigation to see if the company had breached the "standstill obligation" in merger regulations.
Across the Atlantic, the FTC is pressing ahead at a trial to dissolve the union between Illumina and Grail.
Illumina’s stock continues to trade at a substantial discount to its pre-Grail acquisition price.
Verily, Mayo link up on clinical decision support
Verily and Mayo Clinic will be collaborating on the development of a clinical decision support tool to improve cardiovascular and cardiometabolic disease outcomes.
Mayo will provide the curated clinical content, while Verily will bring in the data analytics tech to generate insights.
This collaboration is part of a two-year agreement inked by the companies.
Medtronic still waiting diabetes to sweeten
Medtronic had a stronger-than-expected start to its fiscal 2022, but the diabetes unit continues to be a sore point.
The company is losing share in the US diabetes market, as several key innovations and growth drivers are awaiting the FDA green light.
Also awaiting market clearance - from European regulators - is Medtronic’s surgical robot Hugo. The system is anticipated to bring a major uplift to the medtech’s surgery business.
For related analysis, see Wider View: What’s leading and lagging at Medtronic
AllStripes sees abundant opp in paucity of rare disease therapies
Lux Capital-backed AllStripes is fueling its activities in rare disease R&D with $50 million of series B funds it has raised.
The company will launch 100 new rare disease research programmes, which will be driven by its tech platform designed to shorten the development path of new therapies.
To read more about AllStripes’ technology, see One To Watch: AllStripes to rev up rare disease R&D with one-of-a-kind offering
In case you missed it…
Did you like this article?